Many in the sector have analysed the Interministerial Decree on the new negotiation criteria published in the Official Journal on 24 July 2020, making the necessary comparisons with CIPE Resolution 3/2001.
We at Pharma Value have tried to change our perspective, attempting to understand from an analysis of the frequency of use of certain words, the orientations of the new decree. What jumps out at us, however, are not the words that are most present, but those that are missing. What I do not mention - in fact - does not exist.
The word benefit appears only once, but in reference to the lack of it;
Words concerning the semantic field of innovation appear only once, but in reference to negotiating models and not to drugs.
We NEVER talk about sustainability, innovation, incremental innovation and the clinical benefits of a drug. What do you think?
Draft document on the evaluation criteria for the attribution of therapeutic innovativeness
On March 12, 2025, AIFA published the draft document on the “Evaluation Criteria for the Attribution of Therapeutic Innovation and the Management of Antiinfective Agents for Multidrug-Resistant
9 April 2025
